Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-antibiotic linolenic acid + polaprezinc triple therapy vs bismuth quadruple therapy for first-line Helicobacter pylori eradication
ChiCTR2000037961Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of Alpha-linolenic acid and polaprezinc in Helicobacter pylori infection (3 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Helicobacter pylori eradication by 13C urea breath test. Started Sep 2020; status: recruiting.
02
Drugs
Alpha-linolenic acidpolaprezinc
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2000037961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037961.